Hiking Cigarette Prices Discourages Teens From Taking Up the Habit

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 7
Volume 10
Issue 7

WASHINGTON-A long-term University of Michigan study of smoking among 8th and 10th graders indicates that raising the price of cigarettes can prevent some youths from beginning to use tobacco products. The researchers examined three initiation points: any smoking at all (including experimentation), daily smoking, and smoking a half-pack or more a day. Depending on the type of initiation, an increase of 10% in the price of cigarettes decreased the probability that an adolescent would begin smoking by 3% to 10%.

WASHINGTON—A long-term University of Michigan study of smoking among 8th and 10th graders indicates that raising the price of cigarettes can prevent some youths from beginning to use tobacco products. The researchers examined three initiation points: any smoking at all (including experimentation), daily smoking, and smoking a half-pack or more a day. Depending on the type of initiation, an increase of 10% in the price of cigarettes decreased the probability that an adolescent would begin smoking by 3% to 10%.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content